Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Quintiles IMS Holdings Inc (NYSE:Q) announced its new collaboration to provide clearer and more proactive insight into how anti-cancer treatments are used in actual practice across key European markets. The study will involve the use of Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Merck KGaA (OTCPK:MKGAF)(OTCPK:MKGAY) and Eli Lilly (NYSE:LLY) products.
The study will help to remove the inconsistencies and information gaps in relation to how oncology products are used, for which types of patients and indications and in what sequences and combinations. The company did not offer financial details of the deal.

Patterson Companies (NASDAQ:PDCO) stock dipped to its 52-weeks low after missing Q2 earnings expectations. The company also slashed is guidance for the FY2017. PDCO now expects FY 2017 EPS in the range of $2.25-$2.35, while its earlier outlook was in the range of $2.60-$2.70. The new forecast is also well below the $2.64 analyst consensus estimate. The company cited slow U.S. dental market and challenges with branded pharma companies in the animal health business.
Patterson Companies also failed to provide updates about its potential collaboration with Amazon. The deal pertained to the distribution of its products and was expected to help reduce related costs.

• PAREXEL (NASDAQ:PRXL) signed an accelerated share repurchase agreement with HSBC Bank USA for purchase an aggregate of $200M in common stock.
• Taro Pharmaceuticals (NYSE:TARO) has announced the appointment of Uday Baldota as CEO effective on or about April 1, 2017. He currently serves as EVP & Chief Financial Officer at Sun Pharmaceutical Industries.

• The European Commission has approved the use of Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment in conjunction with Seattle Genetics' ADCETRIS (brentuximab vedotin).
• The FDA approves the use of GlaxoSmithKline's (NYSE:GSK) FluLaval Quadrivalent (influenza vaccine) in children ages six months and older. Its previous labeling was for individuals at least three years old.

• Allergan (NYSE:AGN) purchased Chase Pharma with an upfront payment of $125 million and potential milestone payments based on sales for Chase's CPC-201, and certain backup compounds. Chase Pharma is a clinical-stage biotech and it focuses on developing treatments for neurodegenerative disorders including Alzheimer's disease.
• Medigus (NASDAQ:MDGS) enters into a distribution agreement with INNOVAMEDICA S.p.A. Under the terms of the four-year contract, INNOVAMEDICA will be obliged to purchase at least €1M of Medigus Untrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement. The contract will be effective from January 1.

No secondary offerings to report.

No IPOs to report.

• Cellectis (NASDAQ:CLLS) announced its third quarter loss at -€0.36 per share.
• uniQure (NASDAQ:QURE) announced its third quarter loss at EUR0.54/share, Revenue for the quarter was reported at EUR6.5 million.

• Oppenheimer initiates coverage of TherapeuticsMD (NYSEMKT:TXMD), initial rating Outperform, $12 price target.
• Aegis Capital initiates coverage of Momenta Pharmaceuticals (NASDAQ:MNTA), Initial rating Hold, $15 price target.

None to report.

Gainers (% price change) Last Trade Change Mkt Cap
Dynavax Tech. Corp. DVAX 5.20 +0.45 (9.47%) 202.48M
Immunomedics, Inc. IMMU 3.56 +0.23 (6.91%) 398.71M
Derma Sciences Inc DSCI 4.60 +0.20 (4.55%) 133.06M
OraSure Tech., Inc. OSUR 8.94 +0.34 (3.95%) 497.65M
Zogenix, Inc. ZGNX 13.30 +0.45 (3.50%) 350.16M
Losers (% price change)
Patterson Companies, Inc. PDCO 39.56 -7.95 (-16.73%) 4.01B
Medtronic PLC MDT 73.60 -6.98 (-8.66%) 112.56B
Insys Therapeutics Inc INSY 12.27 -0.99 (-7.47%) 868.18M
Fluidigm Corporation FLDM 5.81 -0.46 (-7.34%) 173.32M
Momenta Pharmaceuticals MNTA 13.55 -0.97 (-6.71%) 1.03B
Most Actives (dollar volume)
Medtronic PLC MDT 73.60 -6.98 (-8.66%) 112.56B
Johnson & Johnson JNJ 112.74 -2.26 (-1.97%) 305.76B
Pfizer Inc. PFE 31.33 -0.24 (-0.76%) 190.67B
Celgene Corporation CELG 120.97 -3.19 (-2.57%) 95.46B
UnitedHealth Group Inc UNH 152.26 +1.85 (1.23%) 145.85B